

# Ventilatory Impairments Associated with Parkinson's Disease: A Systematic Review and Meta-Analysis

Laura López-López<sup>a</sup> Janet Remedios Rodríguez-Torres<sup>a</sup>

Lawrence Patrick Cahalin<sup>b</sup> Irene Cabrera-Martos<sup>a</sup> Irene Torres Sánchez<sup>a</sup>

Marie Carmen Valenza<sup>a</sup>

<sup>a</sup>Department of Physical Therapy, Faculty of Health Sciences. University of Granada, Granada, Spain; <sup>b</sup>Department of Physical Therapy, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA

## Keywords

Parkinson's disease · Pulmonary function · Levodopa

## Abstract

**Background:** The peripheral and central repercussions of Parkinson's disease (PD) affect the neuromuscular system producing a loss of muscle strength that can influence the respiratory system. Although several studies have examined various respiratory aspects of PD, to the best of our knowledge no study to date has systematically reviewed the existing data. **Objectives:** To examine the available literature related to the respiratory impairment in PD patients. **Methods:** We used PRISMA guidelines when reporting this review. We searched Pubmed, Cinhal, SciELO, and Cochrane Library, from inception until August 2018. Main variables assessed were forced vital capacity percent predicted (FVC%) and forced expiratory volume in 1 s percent predicted (FEV<sub>1</sub>%) for PD patients. **Results:** Six studies were included in this systematic review and meta-analysis. The obtained results concluded that PD patients present poorer pulmonary function when compared to healthy controls. When PD patients were compared between ON and OFF states, the results reviewed are in favour of the ON state. In the meta-analysis performed for FVC% and FEV<sub>1</sub>%, the results fail to find significant differ-

ences between PD patients and controls ( $p = 0.336$  and  $p = 0.281$ , respectively), and between PD ON and OFF states ( $p = 0.109$  and  $p = 0.059$ , respectively). **Conclusions:** We conclude that PD patients have impaired respiratory capacities that are related to the PD severity, time since diagnosis, and OFF state. Adequate follow-up of the respiratory function and studies focused on PD phenotypes have to be considered in future studies.

© 2021 S. Karger AG, Basel

## Introduction

Among neurodegenerative diseases, Parkinson's disease (PD) has a high incidence and rate of disability. Although the clinical presentation and evolution of PD patients are heterogeneous, the disability associated with it has different causes involving the gradual loss of motor and non-motor function associated with this pathology [1].

PD is characterized by a profound and selective loss of nigrostriatal dopaminergic neurons that provokes motor symptoms consisting in the cardinal triad of bradykinesia, rigidity, and tremor, accompanied by non-motor

PROSPERO registration ID: CRD42018105121.

symptoms such as mood changes, cognitive decline, pain, sleep disturbance, and autonomic dysfunction [2]. The related peripheral and central repercussions of PD affect the neuromuscular system showing loss of movement control and muscle strength that can influence the respiratory system [3].

Some care guidelines regarding breathing for the adult patients with neuromuscular [4–6] and/or neurodegenerative diseases [7, 8] have been published, but they do not provide sufficient detail about the impairments, rationale, or the best treatments for these types of patients.

Different studies have reported aspiration pneumonia among other complications due to the respiratory dysfunction as the most frequent causes of death in PD patients [9], and aspiration is clearly related to the dysfunction of the protective systems of the upper airways [10]. In fact, the incidence of pneumonia is usually accompanied with deterioration of pharyngeal, laryngeal, and respiratory muscles as well as protective reflexes like the cough reflex. The cough creates an important expiratory airflow that is of great importance in preventing respiratory complications in PD [11]. Additionally, other signs and symptoms like dysphagia, impaired speech, and phonation have been related to the respiratory impairment in PD [12, 13].

The medical management of PD involves levodopa that improves the motor and non-motor symptoms of PD, but the observed improvements usually fluctuate based on dopaminergic administration and compliance. In fact, studies examining particular signs and symptoms during on and off dopaminergic treatment (ON state and OFF state, respectively) have found poorer results during the OFF state.

Although several studies have examined different characteristics of ventilation related to clinical aspects of PD [14, 15], to the best of our knowledge no study to date has systematically reviewed the existing data as it relates directly to respiratory impairments. The purpose of the present study was to systematically review the literature and provide an updated and more comprehensive review related to respiratory impairment in patients with PD taking into account medication effectiveness fluctuation. Additionally, a meta-analysis will be performed in order to analyze the impairments found among the different PD populations.

## Materials and Methods

The protocol for this systematic review was developed consistently with the Preferred Reporting Items for Systematic Review checklist (PRISMA). This review was registered in the International

Prospective Register of Systematic Reviews (PROSPERO registration ID: CRD42018105121).

### Search Strategy

One researcher undertook the initial literature search, scanning all the abstracts to identify eligible studies. If it was unclear whether to include some of the studies, advice was sought from a second researcher, and a consensus opinion was made. We performed a systematic review of the available literature in Pubmed, Cinahl, SciELO, and Cochrane library with the appropriate search terms. Relevant publications were identified by searching the PubMed, Cinahl, and Cochrane library bibliographic databases from inception until August 2018 with combinations of the keywords “pulmonary function AND Parkinson,” “lung AND Parkinson,” “breathing disorders AND Parkinson” (excluding nocturnal disorders), “ventilation AND Parkinson.”

### Study Selection Process

Articles were included if they met the following criteria: (1) the sample population consisted in PD patients, (2) pulmonary function had to be compared between patients and controls, or compared between ON and OFF states, and (3) primary variables had to be forced vital capacity (FVC%) and forced expiratory volume in 1 s (FEV<sub>1</sub>%) both predicted.

Screening of the titles and abstracts of the retrieved studies for relevance was performed by two reviewers, and discrepancies were resolved by consensus. Articles published in languages other than English, French, Spanish, or Portuguese were excluded after the title and abstract screen. Structured abstracts and posters were also excluded. Two reviewers reviewed the remaining articles in their entirety for consistency with the study protocol.

### Quality Assessment and Data Extraction


Two reviewers independently assessed the quality of the studies using the Newcastle-Ottawa Quality Assessment Scale, a simple and widely used tool that scores the methods of observational studies on a scale of 0 (very poor) to 9 (rigorous) [16].

### Statistical Analysis

Where appropriate, study results were pooled, and a meta-analysis was undertaken using Review Manager software (RevMan version 5.1, updated March 2011). The meta-analysis was limited owing to the clinical heterogeneity of the included studies. The  $I^2$  statistic was utilized to determine the degree of heterogeneity, where the percentages quantified the magnitude of heterogeneity: 25% = low, 50% = medium, and 75% = high heterogeneity. Using this scale, if  $I^2$  was 50%, a random effects model was used. All the included variables were of continuous data (FVC% and FEV<sub>1</sub>%) and the MD with 95% CI was used in the analysis.

## Results

The PRISMA flow chart (Fig. 1) shows the number of papers identified on Pubmed, Cinhal, SciELO, and the Cochrane Library, the steps performed in the study selection process, and the reasons for article exclusion.



**Fig. 1.** PRISMA 2009 flow diagram.

A total of 815 studies were retrieved from the electronic search and other sources. From these, 809 studies were excluded due to design, duplicated titles, or absence of the variables of interest. A total of 6 studies [17–22] were included in the analysis.

#### *Risk of Bias*

The subscores of the Newcastle-Ottawa Quality Assessment Scale and total scores for each study are presented in Table 1. The studies presented a moderate quality with a range from 6 to 9 points.

The majority of the studies evaluated fail to refer comparability of cases and controls on the basis of the design or analysis.

Table 2 summarizes participants' demographic and clinical characteristics (severity and duration), respiratory variables, and results.


The majority of the patients included in the studies have a moderate PD severity, with only two studies including mild and severe cases. The age of the patients included ranged from 51 to 69 years and they were of the male gender.

Additionally to the main variables, cough effectiveness (peak expiratory flow), respiratory muscle strength (maximal inspiratory pressure, sniff nasal inspiratory pressure), and physiological response to hypercapnia measures were also included in some studies and considered as secondary variables.

**Table 1.** Newcastle-Ottawa Quality Assessment Scale for case/control studies

Study	Selection				Comparability (2)	Outcome			Total (9)
	definition adequate (1)	representativeness of the cases (1)	selection of controls (1)	definition of controls (1)		assessment (1)	same methods of ascertainment (1)	non-response rate (1)	
Baille et al. [17], 2018	1	1	0	0	0	1	1	1	5
Tambasco et al. [18], 2018	1	1	1	1	0	1	1	1	7
Hampson et al. [19], 2016	1	1	1	0	0	1	1	1	6
Shaheen et al. [20], 2015	1	0	0	0	0	1	1	1	4
Sathyaprabha et al. [21], 2005	1	1	1	1	0	1	1	1	7
De Pandis et al. [22], 2002	1	1	1	1	0	1	1	1	7

Points for each quality measure given in parentheses with total reflecting the sum of these points.

**Fig. 2.** Differences between PD group and control group in FVC%.

### Results Obtained when Comparing PD Patients and Controls

Of the studies that compare PD patients and healthy subjects [17, 20, 21], two of them conclude that FVC% and FEV<sub>1</sub>% were significantly worse in PD. Curiously the study of Baille et al. [17] shows contrary results for the similar variables in favour of PD subjects. Nevertheless, the pooled analysis showed no significant differences between the groups in FVC% (MD 0.81, 95% CI -0.84 to 2.45;  $I^2 = 96.59$ ,  $p = 0.336$ ) (Fig. 2) and in FEV<sub>1</sub>% (MD 0.75, 95% CI -1.62 to 2.12;  $I^2 = 95.29$ ,  $p = 0.281$ ) (Fig. 3).

In the case of the reported secondary variables respiratory muscle strength was evaluated. Baille et al. [17] concluded that PD patients obtained significantly worse results compared to healthy controls in maximal inspiratory pressure and sniff nasal inspiratory pressure. In the comparisons between PD phenotypes, slight differences were found between tremor and akinetic phenotypes.


### Results Obtained when Comparing PD Patients in ON and OFF States

Four studies evaluated FVC% and FEV<sub>1</sub>% in PD patients during ON and OFF treatment states [18, 19, 21, 22]. The majority of them concluded that PD ON groups obtained significantly higher values compared to PD OFF groups, but the study of Hampson et al. [19] shows contrary results. In this line, the pooled analysis showed no significant differences between the groups in FVC% (MD 0.25, 95% CI -0.06 to 0.56;  $I^2 = 41.71\%$ ,  $p = 0.109$ ) (Fig. 4) and in FEV<sub>1</sub>% (MD 0.21, 95% CI -0.01 to 0.42;  $I^2 = 10.43\%$ ,  $p = 0.059$ ) (Fig. 5). A sensitive analysis showed that this heterogeneity in the FVC% was mainly due to the magnitude of the effect found in the study by Hampson et al. [19]. When this study was excluded, the  $I^2$  of the pooled effect became 32.32% with an SMD of 0.40 (95% CI 0.06, 0.74;  $p = 0.003$ ).


**Table 2.** Characteristics of the observational studies on ventilatory impairment on Parkinson's disease

Study	Design	Groups, n	Mean age ± SD, years	Mean disease duration ± SD, years	Disease severity	Primary variables	Secondary variables	Results	
								main results	secondary results
Baile et al. [17], 2018	Cross-sectional case-control study	- Tremor-dominant PD group (n = 15) - Akinetic-dominant PD group (n = 26) - Control group (n = 36)	61.7 ± 7.7	1.9 ± 1.7	Mild to moderate	FVC%, FEV <sub>1</sub> %	MIP %, SNIP%, FEV <sub>1</sub> /FVC	FVC%: PD group > control group (p < 0.05) FEV <sub>1</sub> %: PD group > control group NS	PD group < control group MIP% and SNIP% (p < 0.05) FEV <sub>1</sub> /FVC ns No differences between tremor and akinetic groups
Tambasco et al. [18], 2018	Observational study	- PD ON (n = 34) - PD OFF (n = 34)	69.6 ± 7.3	10.4 ± 4.1	Moderate	FVC%, FEV <sub>1</sub> %	FEV <sub>1</sub> /FVC, VC%, RV%, TLC%	PD ON group > PD OFF group (p < 0.05)	PD ON group > PD OFF group (p < 0.05)
Hampson et al. [19], 2017	Cross-sectional case-control study	- PD ON group (n = 86) - PD OFF group (n = 86)	62.4 ± 8.7	9.4	Mild to moderate	FVC%, FEV <sub>1</sub> %	FEV <sub>1</sub> /FVC %	PD ON group > PD OFF group (NS)	PD ON group > PD OFF group (p < 0.05)
Shaheen et al. [20], 2009	Cross sectional case control study	- PD group (n = 30) - Control group (n = 30)	67.7 ± 8.4	3 ± 2.3	Moderate-severe	FVC%, FEV <sub>1</sub> %	FEV <sub>1</sub> /FVC	PD group < control group (p < 0.05)	PD group < control group (p < 0.05)
Sathyaprabha et al. [21], 2005	Cross-sectional case-control study	- PD ON group (n = 35) - PD OFF group (n = 35) - Control group (n = 35)	51	Not reported	Moderate	FVC%, FEV <sub>1</sub> %	FEV <sub>1</sub> /FVC, PEF%	Control group > PD group (p < 0.05) PD ON group > PD OFF group (p < 0.05)	Control group > PD group (p < 0.05) PD ON group > PD OFF group (p < 0.05)
De Pandis et al. [22], 2002	Observational study	- PD ON (n = 12) - PD OFF (n = 12)	67.66 ± 5.46	14.5 ± 0.66	Severe	FVC%, FEV <sub>1</sub> %	FEV <sub>1</sub> /FVC, PEF, FEF <sub>25-75</sub> , FEF <sub>75</sub> , FEF <sub>50</sub> , FEF <sub>75</sub> , PaO <sub>2</sub> , PaCO <sub>2</sub> , and pH	PD ON group > PD OFF group (p < 0.05)	PD ON group > PD OFF group pH, PaCO <sub>2</sub> , and PEF (p < 0.05) Other variables ns


FVC%, forced vital capacity predicted; FEV<sub>1</sub>%, forced expiratory volume in 1 s predicted; MIP, maximal inspiratory mouth pressure; SNIP, sniff nasal inspiratory pressure; VC, vital capacity; RV, residual volume; TLC, total lung capacity; PEF, peak expiratory flow rate; FEF, forced expiratory flow.



**Fig. 3.** Differences between PD group and control group in FEV<sub>1</sub>%.



**Fig. 4.** Differences between PD ON group and PD OFF group in FVC%.



**Fig. 5.** Differences between PD ON group and PD OFF group in FEV<sub>1</sub>%.

Furthermore, with respect to other spirometric values (total lung capacity, residual volume), gasometric, and cough measurements the obtained results are in favour of ON state groups.

De Pandis et al. [22] compared pH, PaO<sub>2</sub> and PaCO<sub>2</sub> in PD patient ON and OFF states, obtaining significantly higher values for the PD ON group.

## Discussion

This systematic review and meta-analysis aimed to examine the available literature related to the respiratory impairment in patients with PD. The obtained results concluded that PD patients present poorer pulmonary function when compared to healthy controls. When PD patients were compared between ON and OFF states, the results reviewed are in favour of the ON state. Those results have been found significant only for some respiratory variables (FVC, FEV<sub>1</sub>, FEV<sub>1</sub>/FVC, and peak expiratory flow) and in the more severe PD cases.

In the meta-analysis performed for FEV<sub>1</sub>% and FVC%, the results fail to find significant differences between PD patients and controls and between PD states, this can be due to the heterogeneity of the groups' PD profile and to the severity of the disease.

### *Respiratory Differences between PD Patients and Controls*

The characteristics of the patients compared to controls were variable across the studies included. In the majority of the cases, the severity of the disease was moderate to severe, and significant differences were found between PD patients and controls for all measured variables. The study of Baille et al. [17] includes mild severity and promptly diagnosed PD patients, failing to find the same conclusions for respiratory variables. In their study the comparisons between PD and control groups found significant impairments in respiratory muscle strength in favour of controls and significantly better results for respiratory function in favour of PD patients.

The cough effectiveness was compared with controls in the study of Sathyaprabha et al. [21], and they found significant differences between groups in favour of controls. This fact has been previously reported when the prevalence of pneumonia in PD patients was discussed [9].

The results obtained in the meta-analysis, when comparing PD to controls concerning FEV<sub>1</sub>% and FVC% measures, shows no significant differences between

groups. This fact could be explained by the heterogeneity of the stage and diagnosis of the PD subjects included. In this line the study of Baille et al. [17] has been determinant to the results obtained. In view of these results, in PD patients with similar severity, pulmonary impairments can be additionally determined by the disease duration. In fact, a study carried out by Wang et al. [23] found a significant relationship between respiratory impairments and PD duration.

### *Respiratory Differences between PD Patients in the ON/OFF State*

When comparing ON and OFF states among PD patients we found that patients with the PD ON state present better pulmonary function compared to patients with the PD OFF state. Both restrictive and obstructive patterns of pulmonary dysfunction have been described in patients with PD [9]. However, even though levodopa has been considered as the gold standard treatment for PD since its discovery in the early 1960s, its effects on pulmonary function in PD patients remain controversial [24].

This was significant in the studies of De Pandis, Sathyaprabha and Tambasco for FEV<sub>1</sub>%, FVC%, cough efficacy, and gasometric variables. The included PD patients in those studies were similar in PD severity, age of participants, and time since diagnosis. In contrast, the study of Hampson et al. [19] found no significant differences for spirometric variables when comparing ON and OFF states. Those results can be explained by the selection criteria applied to PD patients: their severity was mild to moderate, and all patients who showed American Thoracic Society/European Respiratory Society diagnostic criteria for respiratory impairments were excluded.

Our meta-analysis failed to find significant conclusions when ON/OFF states were compared for FVC% and FEV<sub>1</sub>%. Our results can be pooled due to the study of Hampson et al. [19] and their PD patient's profile that may not reflect the general characteristics of PD patients.

Monteiro et al. [25] carried out a meta-analysis, consisting of 4 trials with a total of 73 patients, and concluded that levodopa improved restrictive parameters of pulmonary dysfunction, probably due to an enhancement in chest wall compliance in the ON phase. These authors also declared that obstructive parameters may improve with levodopa therapy; however, they stated that there is not enough evidence to support this view. Nakane et al. [26] presented similar results to ours, finding a significant improvement in peak expiratory flow, maximal voluntary ventilation, FEV<sub>1</sub>, FVC, and total lung capacity in PD patients receiving levodopa.

### Limitations

The main limitation that emerged from this systematic review and meta-analysis is the lack of studies using the same variables to evaluate pulmonary impairments. Curiously, while spirometry is recognized as gold standard pulmonary function measure [27], only a couple of variables are usually reported by the different authors. In addition, the use of predicted versus non-predicted scores make comparisons difficult among subjects, which impacts the results for meta-analysis. Another limitation of this review was the scarce information about other respiratory variables like cough effectiveness or respiratory muscle strength. While therapeutic respiratory training programmes are usually applied, there is a lack of knowledge about the real and concrete PD profile that is needed to be treated. In this line, it is clear that a scientific and clinical consensus needs to be published about the methods to assess respiratory function in PD patients including pulmonary, cough, and respiratory muscle strength measures. Another limitation of this review is the lack of information provided about the concrete characteristics of PD, related to stage (early vs. more advanced), time since diagnosis, and motor characteristics in the studies where PD patients and healthy subjects were compared. This can be the reason for the discordance between the studies included in the meta-analysis.

### Conclusion

In summary, our results show that PD patients have impaired respiratory capacities that are related to the PD severity, time since diagnosis, and OFF state. When comparing groups (PD vs. controls and ON vs. OFF state), our meta-analysis failed to find significant conclusions; this can be explained by the heterogeneity of the inclusion criteria applied in each study and their small number. Our

results suggest that spirometric studies as well as proper staging of PD may be important factors to be considered in future studies of respiratory function status in patients with PD. Nevertheless, further randomized controlled trials with attention to the stage of PD are necessary to evaluate the efficacy of levodopa on respiratory dysfunction in these patients.

### Disclosure Statement

The authors do not have any conflict of interest.

### Funding Sources

This work was financed jointly by the Fundación Progreso y Salud and Boehringer Ingelheim España SA (Project code: PI-0370-2014), Oximesa, Praxair. The author J.R.R.-T. has received financial support through an FPU (Formación Profesorado Universitario) grant (FPU: 16/01531) of the Spanish Ministry of Education. The author L.L.L.-L. has received financial support through an FPU grant (FPU: 17/00408) of the Spanish Ministry of Education (Spain).

### Author Contributions

M.C.V. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis, including especially any adverse effects.

L.L.L. contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript.

J.R.R.-T. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

L.P.C. contributed substantially to the study design, data analysis, interpretation, and the writing of the manuscript.

I.C.-M. contributed substantially to the study design, data analysis, interpretation, and the writing of the manuscript.

I.T.S. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

### References

- 1 Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. *Arch Neurol*. 2002 Nov;59(11):1724–8.
- 2 Politis M, Wu K, Molloy S, G Bain P, Chaudhuri KR, Piccini P. Parkinson's disease symptoms: the patient's perspective. *Mov Disord*. 2010 Aug;25(11):1646–51.
- 3 Sande de Souza LA, Dionísio VC, Almeida GL. Multi-joint movements with reversal in Parkinson's disease: kinematics and electromyography. *J Electromyogr Kinesiol*. 2011 Apr;21(2):376–83.
- 4 Bott J, Blumenthal S, Buxton M, Ellum S, Falconer C, Garrod R, et al.; British Thoracic Society Physiotherapy Guideline Development Group. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. *Thorax*. 2009 May;64 Suppl 1:i1–51.
- 5 Ambrosino N, Carpenè N, Gherardi M. Chronic respiratory care for neuromuscular diseases in adults. *Eur Respir J*. 2009 Aug;34(2):444–51.
- 6 Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al.; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *Lancet Neurol*. 2010 Feb;9(2):177–89.
- 7 Bede P, Oliver D, Stodart J, van den Berg L, Simmons Z, Ó Brannagáin D, et al. Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. *BMJ Support Palliat Care*. 2011 Dec;1(3):343–8.



- 8 Kristjanson LJ, Aoun SM, Oldham L. Palliative care and support for people with neurodegenerative conditions and their carers. *Int J Palliat Nurs*. 2006;12(8):368–77.
- 9 Sabaté M, González I, Ruperez F, Rodríguez M. Obstructive and restrictive pulmonary dysfunctions in Parkinson's disease. *J Neurol Sci*. 1996 Jun;138(1-2):114–9.
- 10 Shill H, Stacy M. Respiratory function in Parkinson's disease. *Clin Neurosci*. 1998;5(2):131–5.
- 11 Pal PK, Sathyaprabha TN, Tuhina P, Thenarasu K. Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa. *Mov Disord*. 2007 Feb;22(3):420–4.
- 12 Ebihara S, Saito H, Kanda A, Nakajoh M, Takahashi H, Arai H, et al. Impaired efficacy of cough in patients with Parkinson disease. *Chest*. 2003 Sep;124(3):1009–15.
- 13 Fontana GA, Lavorini F, Pistolesi M. Water aerosols and cough. *Pulm Pharmacol Ther*. 2002;15(3):205–11.
- 14 Brown LK. Respiratory dysfunction in Parkinson's disease. *Clin Chest Med*. 1994 Dec;15(4):715–27.
- 15 Bateman DN, Cooper RG, Gibson GJ, Peel ET, Wandless I. Levodopa dosage and ventilatory function in Parkinson's disease. *Br Med J (Clin Res Ed)*. 1981 Jul;283(6285):190–1.
- 16 Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011.
- 17 Baille G, Perez T, Devos D, Deken V, Defebvre L, Moreau C. Early occurrence of inspiratory muscle weakness in Parkinson's disease. *PLoS One*. 2018 Jan;13(1):e0190400.
- 18 Tambasco N, Murgia N, Nigro P, Paoletti FP, Romoli M, Brahim E, et al. Levodopa-responsive breathing discomfort in Parkinson's disease patients. *J Neural Transm (Vienna)*. 2018 Jul;125(7):1033–6.
- 19 Hampson NB, Kiebertz KD, LeWitt PA, Leinonen M, Freed MI. Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations. *Int J Neurosci*. 2017 Mar;127(3):276–84.
- 20 Shaheen HA, Ali MA, Abd Elzaher MA. Parkinson's disease and pulmonary dysfunction. *Egypt J Neurol Psychiat Neurosurg*. 2009;46(1):129–40.
- 21 Sathyaprabha TN, Kapavarapu PK, Pall PK, Thenarasu K, Raju TR. Pulmonary functions in Parkinson's disease. *Indian J Chest Dis Allied Sci*. 2005 Oct-Dec;47(4):251–7.
- 22 De Pandis MF, Starace A, Stefanelli F, Maruzzo P, Meoli I, De Simone G, et al. Modification of respiratory function parameters in patients with severe Parkinson's disease. *Neurol Sci*. 2002 Sep;23(2 Suppl 2):S69–70.
- 23 Wang Y, Shao WB, Gao L, Lu J, Gu H, Sun LH, et al. Abnormal pulmonary function and respiratory muscle strength findings in Chinese patients with Parkinson's disease and multiple system atrophy—comparison with normal elderly. *PLoS One*. 2014 Dec;9(12):e116123.
- 24 Cotzias GC. L-Dopa for parkinsonism. *N Engl J Med*. 1968 Mar;278(11):630.
- 25 Monteiro L, Souza-Machado A, Valderramas S, Melo A. The effect of levodopa on pulmonary function in Parkinson's disease: a systematic review and meta-analysis. *Clin Ther*. 2012 May;34(5):1049–55.
- 26 Nakano KK, Bass H, Tyler HR. Levodopa in Parkinson's disease: effect on pulmonary function. *Arch Intern Med*. 1972 Sep;130(3):346–8.
- 27 Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.; ATS/ERS Task Force. Standardisation of spirometry. *Eur Respir J*. 2005 Aug;26(2):319–38.